MYC and hematopoietic and lymphoid system neoplasm: In particular, another recent finding [114] has confirmed that METTL3 can identically enhance the expression of c-MYC protein in leukemic cells by means of increasing the level of m6A modification of c-Myc gene mRNA, thereby inhibiting cell differentiation and promoting the self-renewal of leukemic cells, and exerting oncogenic effects in hematological tumors.